# US 2026/0029402 A1 · Garp as a biomarker and biotarget in t-cell malignancies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0029402 A1
- Document ID: US20260029402A1
- Status: Published application
- Kind: A1
- Application number: 18/997,118
- Filed: 2023-07-21
- Published: 2026-01-29
- Earliest claimed: 2022-07-22
- Assignees: Institut National de la Sante et de la Recherche Medicale; Assistance Publique-Hopitaux de Paris; Université Paris Cité; Universite Paris Est Creteil Val De Marne
- Applicants: Institut National De La Santé Et De La Recherche MéDicale; Assistance Publique-HôPitaux De Paris; Université Paris Cité; Université Paris Est CréTeil Val De Marne
- Inventors: Armand BENSUSSAN; Francois LEMONNIER; Jerome GIUSTINIANI; Nicolas ORTONNE; Adele DE MASSON; Martine BAGOT
- Web page: https://patentgrep.com/patent/US20260029402A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- C07K 16/18: against material from animals or humans
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies.

## Claims

### Claim 1

A method of diagnosing and treating a T-cell malignancy in a patient in need thereof comprising
detecting an expression level of GARP in a sample obtained from the patient, determining that the expression level differs from that of a reference value, and treating the subject determined to have an expression level that differs from that of the reference value with a GARP inhibitor and/or an agent capable of inducing cell death of GARP expressing cancer cells.

### Claim 2 (depends on 1)

The method of claim 1 wherein the T-cell malignancy is a T-cell lymphoma or a T-cell leukemia.

### Claim 3 (depends on 1)

The method of claim 1 wherein the T-cell malignancy is Sézary syndrome, Hepatosplenic T-cell lymphoma, Angioimmunoblastic T-cell lymphoma, NK/T-cell lymphoma or T-cell Acute Lymphoblastic Leukemia.

### Claim 4 (depends on 1)

The method of claim 1 wherein the T-cell malignancy is a cutaneous T-cell lymphoma.

### Claim 5 (depends on 1)

The method of claim 1 wherein the T-cell malignancy is Sézary syndrome.

### Claim 6 (depends on 1)

The method of claim 1 that further comprises detecting the expression level of at least one further marker selected from the group consisting of CD3, CD4, KIR3DL2, PLS3, Twist and NKp46.

### Claim 7

A method of treating a T-cell malignancy in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a GARP inhibitor and/or an agent capable of inducing cell death of GARP expressing cancer cells.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The method of claim 7 wherein the T-cell malignancy is a T-cell lymphoma or a T-cell leukemia.

### Claim 10 (depends on 7)

The method of claim 7 wherein the T-cell malignancy is Sézary syndrome, Hepatosplenic T-cell lymphoma, Angioimmunoblastic T-cell lymphoma, NK/T-cell lymphoma or T-cell Acute Lymphoblastic Leukemia.

### Claim 11 (depends on 9)

The method of claim 9 wherein the T-cell lymphoma is cutaneous T-cell lymphoma.

### Claim 12 (depends on 9)

The method of claim 9 wherein the T-cell lymphoma is Sézary syndrome.

### Claim 13 (depends on 7)

The method of claim 7 wherein the GARP inhibitor or the agent is an antibody having binding affinity for GARP.

### Claim 14 (depends on 13)

The method of claim 13 wherein the antibody is directed against at least one extracellular domain of GARP.

### Claim 15 (depends on 13)

The method of claim 13 wherein the antibody depletes GARP expression cancer cells.

### Claim 16 (depends on 15)

The method of claim 15 wherein the antibody mediates antibody-dependent cell-mediated cytotoxicity.

### Claim 17 (depends on 13)

The method of claim 13 wherein the antibody is a multispecific antibody comprising a first antigen binding site directed against GARP and at least one second antigen binding site directed against an effector cell.

### Claim 18 (depends on 13)

The method of claim 13 wherein the antibody is conjugated to a cytotoxic moiety.

### Claim 19 (depends on 7)

The method of claim 7 wherein the agent is a CAR-T cell wherein the CAR comprises at least an extracellular antigen binding domain specific for GARP.
